Diaverum appoints Krisja Vermeylen to its Board of Directors

Report this content

Malmö, 1 September 2020: Diaverum, a global leading provider of renal care services, announces the appointment of Krisja Vermeylen to its Board of Directors, and as Chair of the Remuneration Committee.

Krisja brings more than 30 years of experience in healthcare and big pharma, the last 20 spent in various management positions at Novo Nordisk and prior to that, several years at Pharmacia (today Pfizer). Ms. Vermeylen is a pharmacist by training and holds a master's degree in pharmaceutical sciences from the University of Antwerp (UIA, RUCA), Belgium.

“Krisja Vermeylen is a very experienced board member, particularly within the international healthcare sector. We are confident that she will add great value to the board, and that Diaverum will benefit from her insights, judgment and counsel”, says Kenneth Bengtsson, Chairman Diaverum.

She holds more than 20 years of experience of various board assignments, and is currently chairman of the Spencer Stuart Brussels Advisory Board and an Independent Director of Morphosys AG.

I am really looking forward to supporting Diaverum in its ambition to deliver high quality renal care and as such improving the lives of many patients and their families”, says Krisja Vermeylen about her new assignment.

For more information, please contact:
Kirsty Bashforth SVP, Chief People & Communications Officer 
Phone: +44 7748 320161  
E-mail: Kirsty.Bashforth@diaverum.com

Diaverum is a leading global provider in renal care services, serving 39,500 patients with 6 million treatments annually. The company’s core service is haemodialysis but provides a broad portfolio of treatments ranging from preventive care, peritoneal dialysis and home care to patient care coordination and transplantation services. Diaverum employs more than 12,000 employees and operates more than 400 clinics in 22 countries globally. Diaverum has its head office in Malmö, Sweden www.diaverum.com